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The incidence of cardiac arrhythmia and heart failure contin-
ues to rapidly increase, leading to a growing epidemic which
constitutes a serious financial burden for society (Chugh et al.,
2014; Melman et al., 2014). Despite the standard therapeutic
strategies to treat adverse cardiac remodeling that precedes the
development of arrhythmia and overt heart failure, their preva-
lence is still increasing and their morbidity and mortality have
not been largely improved (Melman et al., 2014; Sardar et al.,
2014). Continued and deeper understanding of the molecular
mechanisms responsible for arrhythmia and heart failure will help
identify novel effective therapies.
In the past few years, research has implicated the contribu-
tion of genetic and epigenetic factors to arrhythmia and heart
failure. This research hot topic entitled “Genetic and epigenetic
basis of arrhythmia and heart failure” provides a snapshot in
this area. The 10 selected papers in this special research topic
will enhance current understanding of the genetic and epigenetic
basis of arrhythmia and heart failure, and also will expand our
knowledge on novel interventions.
In this issue, genetic aspects of arrhythmia were described by 3
different groups. Crump and Abbott (2014) provided an update
about arrhythmogenic KCNE gene variants and their roles, and
also discussed several challenges in this area. Interestingly, Nielsen
et al. (2013) showed that the Ito regulatory subunit Klf15 was
not associated with early-onset long atrial fibrillation in their
cohort. Besides familial atrial fibrillation, genome wide associ-
ation studies (GWAS) have identified common variants in the
general population for atrial fibrillation. Yao et al. (2014) gave
an overview on the paired-like homeodomain 2, which was iden-
tified as a common variant to be involved in atrial fibrillation,
highlighting the potential of paired-like homeodomain 2 as a new
therapeutic target.
Duygu et al. (2013) provided an outstanding overview about
the genetics and epigenetics of arrhythmia and heart fail-
ure. Besides highlighting specific genetic mutations associated
with heart failure, they also summarized epigenetic mechanisms
including DNA methylation, ATP-dependent chromatin remod-
eling, histone modification and RNA-based mechanisms, high-
lighting the relationship among epigenetics, heart failure and
arrhythmiaogenesis. Finally, they also introduced a discussion on
the role of non-coding RNAs especially microRNAs (miRNAs,
miRs) in heart failure and arrhythmia.
miRNAs are endogenous non-coding RNAs which post-
transcriptionally regulate gene expressions (Condorelli et al.,
2014). A single miRNA can target several target genes while an
individual gene can be regulated by many miRNAs (Viereck et al.,
2014). Therefore, miRNAs have been considered as central reg-
ulators of gene expression, which participate in many essential
biological processes including cellular proliferation, differentia-
tion, apoptosis, and cardiac metabolism (Condorelli et al., 2014;
Viereck et al., 2014). Dysregulations of miRNAs have been con-
nected tomany cardiovascular diseases, including arrhythmia and
heart failure (Kwekkeboom et al., 2014; Melman et al., 2014). In
this special research topic, 4 opinion articles have been provided
about miRNAs in arrhythmia and heart failure. Fu et al. (2014)
presented the current understanding about miRNAs as novel
players in atrial fibrillation, a most common form of arrhythmia
that affects at least 1% persons in the general population. Changes
in cardiac structure and function (termed diabetic cardiomyopa-
thy) may play a role in the increased incidence of sudden death
and heart failure in the diabetic patients. Zhou et al. (2014) sum-
marized dysregulations of miRNAs in diabetic cardiomyopathy.
Interestingly, changes of circulating miRNAs in diabetic patients
have also been noted, although their associations with diabetic
cardiomyopathy are unclear. Better understanding of circulating
miRNAs in diabetic cardiomyopathy would help the development
of biomarkers and novel therapies. Ageing is correlated with an
increase in the incidence of both heart failure (particularly heart
failure with preserved ejection fraction) and atrial fibrillation.
Considering the rapid increase in the geriatric population, it is
urgent to understand the role of miRNAs in aging. Zhuo et al.
(2014) provided some insights into the dysregulation of miR-
NAs in aging-related heart failure. New therapeutics via targeting
microRNAs are being developed based on the detailed under-
standing of the role of miRNAs in heart failure and arrhythmia
using either antagomirs or mimics (Kwekkeboom et al., 2014).
In contrast to the previous articles on the role of miRNAs in
pathological heart diseases, Fu et al. (2013) dissected the role of
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miRNAs in physiological hypertrophy. Physiological hypertrophy,
which is associated with exercise and pregnancy, is not associated
with pathological processes like apoptosis and fibrosis, and unlike
its counterpart (pathological hypertrophy), is not the harbinger
of sudden death or heart failure. Given the known beneficial
effects of exercise on cardiovascular outcomes, a better under-
standing of miRNAs in physiological hypertrophy may lead to
novel miRNA-based therapies for heart failure.
Finally Stagnaro and Caramel (2013) proposed a “Quantum
Biophysics Semeiotics” (QBS) microcirculatory theory of
atherosclerosis, which could be used for diagnosis or therapies.
In addition, Tao et al. (2013) provided their prospects of using
Qiliqiangxin, a traditional Chinese medicine, in the treatment
of heart failure potentially through epigenetic regulation of
regeneration.
In conclusion, this research topic offers a detailed and updated
summary about genetic and epigenetic basis of arrhythmia and
heart failure, and provides a forum for discussion on ways to
translate these genetic and epigenetic findings into novel therapies
for arrhythmia and heart failure.
REFERENCES
Chugh, S. S., Roth, G. A., Gillum, R. F., andMensah, G. A. (2014). Global burden of
atrial fibrillation in developed and developing nations. Glob. Heart 9, 113–119.
doi: 10.1016/j.gheart.2014.01.004
Condorelli, G., Latronico, M. V., and Cavarretta, E. (2014). microRNAs in cardio-
vascular diseases: current knowledge and the road ahead. J. Am. Coll Cardiol. 63,
2177–2187. doi: 10.1016/j.jacc.2014.01.050
Crump, S. M., and Abbott, G. W. (2014). Arrhythmogenic KCNE gene vari-
ants: current knowledge and future challenges. Front. Genet. 5:3. doi:
10.3389/fgene.2014.00003
Duygu, B., Poels, E. M., and da Costa Martins, P. A. (2013). Genetics
and epigenetics of arrhythmia and heart failure. Front. Genet. 4:219. doi:
10.3389/fgene.2013.00219
Fu, S., Huang, L., Wang, Y., Li, X., Li, J., and Xiao, J. (2014). MicroRNA as a novel
player in atrial fibrillation. Front. Genet. 5:97. doi: 10.3389/fgene.2014.00097
Fu, S., Zhuo, R., Yao, M., Zhang, J., Zhou, H., and Xiao, J. (2013).
MicroRNA basis of physiological hypertrophy. Front. Genet. 4:253. doi:
10.3389/fgene.2013.00253
Kwekkeboom, R. F., Lei, Z., Doevendans, P. A., Musters, R. J., and Sluijter,
J. P. (2014). Targeted delivery of miRNA therapeutics for cardiovascular
diseases: opportunities and challenges. Clin. Sci. (Lond.) 127, 351–365. doi:
10.1042/CS20140005
Melman, Y. F., Shah, R., and Das, S. (2014). MicroRNAs in heart failure:
is the picture becoming less miRky? Circ. Heart Fail. 7, 203–214. doi:
10.1161/CIRCHEARTFAILURE.113.000266
Nielsen, M.W., Olesen, M. S., Refsgaard, L., Haunsø, S., and Svendsen, J. H. (2013).
Screening of the ito regulatory subunit klf15 in patients with early-onset lone
atrial fibrillation. Front. Genet. 4:88. doi: 10.3389/fgene.2013.00088
Sardar, M. R., Saeed, W., and Kowey, P. R. (2014). Antiarrhythmic drug therapy for
atrial fibrillation. Cardiol. Clin. 32, 533–549. doi: 10.1016/j.ccl.2014.07.012
Stagnaro, S., and Caramel, S. (2013). The key role of vasa vasorum inherited remod-
eling in QBS microcirculatory theory of atherosclerosis. Front. Genet. 4:55. doi:
10.3389/fgene.2013.00055
Tao, L., Shen, S., and Li, X. (2013). Future prospects of Qiliqiangxin on
heart failure: epigenetic regulation of regeneration. Front. Genet. 4:221. doi:
10.3389/fgene.2013.00221
Viereck, J., Bang, C., Foinquinos, A., and Thum, T. (2014). Regulatory RNAs
and paracrine networks in the heart. Cardiovasc. Res. 102, 290–301. doi:
10.1093/cvr/cvu039
Yao, M., Cao, Y., Zhu, H., Chen, Y., Zhu, T., and Xiao, J. (2014).Paired-like home-
odomain 2: a novel therapeutic target for atrial fibrillation? Front. Genet. 5:74.
doi: 10.3389/fgene.2014.00074
Zhou, Q., Lv, D., Chen, P., Xu, T., Fu, S., Li, J., et al. (2014). MicroRNAs in
diabetic cardiomyopathy and clinical perspectives. Front. Genet. 5:185. doi:
10.3389/fgene.2014.00185
Zhuo, R., Fu, S., Li, S., Yao,M., Lv, D., Xu, T., et al. (2014). DesregulatedmicroRNAs
in aging-related heart failure. Front. Genet. 5:186. doi: 10.3389/fgene.2014.00186
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 29 January 2015; accepted: 12 February 2015; published online: 03 March
2015.
Citation: Xiao J, Sluijter JPG, Das S, Yang Y and Shen Z (2015) A snapshot of genetic
and epigenetic basis of arrhythmia and heart failure. Front. Genet. 6:74. doi: 10.3389/
fgene.2015.00074
This article was submitted to Epigenomics and Epigenetics, a section of the journal
Frontiers in Genetics.
Copyright © 2015 Xiao, Sluijter, Das, Yang and Shen. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Genetics | Epigenomics and Epigenetics March 2015 | Volume 6 | Article 74 | 2
